AIM ImmunoTech Inc.

(NYSE:AIM)

By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Contact Information

Website: www.aimimmuno.com
Email: IR@AIMimmuno.com
Main Phone: +1 352 448-7797
Address: 2117 SW Highway 484
Address 2: Suite B
State: FL
City / Town: Ocala
Country: US
Postal Code: 34473

Issuer Information

Exchange: AMX
CEO: Thomas K. Equels
Employees: 26
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A